The next challenge will be the creation of a tool to determine the economic effects of pharmacists’ interventions. Up to now, there is the possibility to enter direct cost savings that can be generated through the rational use of medicines. The calculation of indirect cost savings (for example reduction of the length of stay, reduction of costs arising from inappropriate dosage, adverse effects or interactions, decrease of morbidity and/or mortality) is much more difficult, and therefore has not yet been included into DokuPIK.